Evidence map›Paper›PMID 20676949›Full record

ReviewMedizinische Klinik (Munich, Germany : 1983)2010

[New drugs for the treatment of constipation].

Birgit Adam, Tobias Liebregts, Guido Gerken

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Medizinische Klinik (Munich, Germany : 1983), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Birgit AdamKlinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen, Germany. birgit.adam@uk-essen.de
Tobias Liebregts
Guido Gerken
Essen University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review introduces new therapeutic options in the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Therefore, prucalopride and lubiprostone are discussed including their mechanisms and side effects. In addition, other substances that are currently under evaluation such as renzapride and linaclotide are described, since recent results showed a significant effect in patients with constipation. Thus, after the withdrawal of tegaserod due to cardiac side effects, new potent drugs are now available for the treatment of constipation.

Indexed as

AlprostadilBenzamidesBenzofuransBridged Bicyclo Compounds, HeterocyclicCatharticsChloride Channel AgonistsConstipationHumansIrritable Bowel SyndromeLubiprostonePeptidesRandomized Controlled Trials as TopicReceptors, Guanylate Cyclase-CoupledReceptors, Serotonin, 5-HT4AlprostadilBenzamidesBenzofuransBridged Bicyclo Compounds, HeterocyclicCatharticsChloride Channel AgonistslinaclotideLubiprostonePeptidesprucaloprideReceptors, Guanylate Cyclase-CoupledReceptors, Serotonin, 5-HT4renzapride

Identifiers

PMID20676949
OpenAlexW1561836428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.